Fin Trust Capital Advisors, LLC Ventyx Biosciences, Inc. Transaction History
Fin Trust Capital Advisors, LLC
- $577 Million
- Q3 2024
A detailed history of Fin Trust Capital Advisors, LLC transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Fin Trust Capital Advisors, LLC holds 414 shares of VTYX stock, worth $687. This represents 0.0% of its overall portfolio holdings.
Number of Shares
414
Previous 414
-0.0%
Holding current value
$687
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding VTYX
# of Institutions
134Shares Held
55.2MCall Options Held
81.4KPut Options Held
148K-
Black Rock Inc. New York, NY4.77MShares$7.92 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.48MShares$7.44 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC4.27MShares$7.09 Million0.0% of portfolio
-
Sio Capital Management, LLC New York, NY4.05MShares$6.72 Million3.31% of portfolio
-
Ubs Group Ag3.78MShares$6.28 Million0.0% of portfolio
About Ventyx Biosciences, Inc.
- Ticker VTYX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,527,200
- Market Cap $93.8M
- Description
- Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...